Laurent Bertoletti Invites You to The INNOVTE and GITA Joined Meeting on Hormones and Thrombosis
Laurent Bertoletti, University Professor and Hospital Practitioner at Jean Monnet University, Saint-Etienne, reposted from INNOVTE on LinkedIn:
”From contraception to pregnancy, menopause to oncology, hormonal contexts profoundly influence thrombotic risk.
The INNOVTE network and GITA are joining forces to organize the “Hormones and Thrombosis” meeting on November 28, 2025, in Paris.
123 boulevard de Grenelle, Paris 15th arrondissement
Full program below – registration now open.
A day of training and dialogue between specialties to better understand how hormonal contexts—contraception, pregnancy, menopause, hormone treatments, or cancer—modulate thrombotic risk.
Translated with DeepL.com (free version)”
Quoting INNOVTE‘s post:
”Réunion GITA “Hormones et Thromboses” – 28 novembre 2025 in Paris
INNOVTE is pleased to support this scientific day organized by GITA, dedicated to the links between hormones and thrombotic risk.
This day, focused on sharing and scientific reflection, will bring together experts from various disciplines (vascular medicine, hematology, endocrinology, etc.) around a rich program:
- scientific news,
- discussions of clinical cases,
- exchanges of experience and research perspectives.
Friday, November 28, 2025
From 8:30 a.m. to 4:30 p.m.
123 Boulevard de Grenelle, Paris
There are still a few places left!
Register here.
With the organizing committee: Laurent Bertoletti, Francis Couturaud, Antoine Achkar, Ismail Elalamy”
Stay updated with Hemostasis Today.
-
Oct 28, 2025, 14:27Maha Othman on 10-Year Anniversary of the CanVECTOR Research Network!
-
Oct 28, 2025, 14:00Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
-
Oct 28, 2025, 13:31Laurent Bertoletti Invites You to The INNOVTE and GITA Joined Meeting on Hormones and Thrombosis
-
Oct 28, 2025, 12:28Courtney Lawrence: Honored to Team Up with BET on Blood at AABB 2025
-
Oct 27, 2025, 19:45Benedikt Lorenz on Liver Failure and Coagulation – Myths, Traps, and Bad Habits
-
Oct 28, 2025, 13:09Gregory Piazza on CORONA-VTE Network Analysis
-
Oct 27, 2025, 18:42Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
-
Oct 27, 2025, 13:30Fabrice Cognasse: When Platelets Meet Artificial Intelligence!
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 15:10David McIntosh: Making Measurable Progress – Towards a World in Which No-one Ever Dies from Lack of a Vital Plasma-Derived Medicine
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation